Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
McKesson
Federal Trade Commission
Cerilliant
Teva
Express Scripts
Julphar
Fish and Richardson
Accenture

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,408,893

« Back to Dashboard

Which drugs does patent 9,408,893 protect, and when does it expire?

Patent 9,408,893 protects ADLYXIN and is included in one NDA.

This patent has sixteen patent family members in nineteen countries.
Summary for Patent: 9,408,893
Title:Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
Inventor(s): Niemoeller; Elisabeth (Frankfurt am Main, DE), Muehlen-Bartmer; Isabel (Frankfurt am Main, DE), Silvestre; Louise (Paris, FR), Boka; Gabor (Paris, FR), Miossec; Patrick (Paris, FR)
Assignee: Sanofi-Aventis Deutschland GMBH (Frankfurt am Main, DE)
Application Number:13/595,590
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,408,893

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS ➤ Sign Up
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,408,893

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11179149Aug 29, 2011

International Patents Family Members for US Patent 9,408,893

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2846413 ➤ Sign Up
China 103917241 ➤ Sign Up
Cyprus 1116803 ➤ Sign Up
Denmark 2750699 ➤ Sign Up
European Patent Office 2750699 ➤ Sign Up
Spain 2550357 ➤ Sign Up
Hong Kong 1196267 ➤ Sign Up
Croatia P20151068 ➤ Sign Up
Hungary E027989 ➤ Sign Up
Japan 2014527063 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Covington
QuintilesIMS
Chubb
Farmers Insurance
Johnson and Johnson
Moodys
Baxter
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot